Novavax reports positive phase 1 data on its Covid-19 vaccine candidate

The study found the candidate to both be generally well-tolerated and elicit “robust antibody responses,” the company said Tuesday.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.